ClinicalTrials.gg
RecruitingNCT07329777ATOM-MYUpdated Jan 9, 2026

Atropine in the Treatment of Myopia Study in Malaysia

A Phase 3 interventional study of Low dose atropine sulfate eye drops and Placebo in Myopia Progression, sponsored by IDB VisionCare SDN BHD. Recruiting at 2 sites in Malaysia. Open to participants aged 5 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by IDB VisionCare SDN BHD · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
5 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Planned enrollment
27th of 54
144 · median 144
Started
2025
with 4 others
Phase 3
13 of 54
5 open now
Primary completion
2027-09
later than 15 of 23 live
Registered
47th of 54
by date

Among the 54 studies testing atropine in Myopia, this one is the 27th largest by planned enrollment, is one of 5 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 15 of the 23 other live ones, and was the 47th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 5 Years to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

This clinical trial is designed to assess the efficacy and safety of Atropine Sulphate 0.025% w/v Eye Drops compared to placebo in a randomized, double-blind, placebo-controlled study for the management of myopia progression in children.

Read the detailed description

Myopia represents the most prevalent refractive error globally, with its incidence rising significantly over recent decades, particularly in East Asian populations. Current projections estimate that by the year 2050, nearly 50% of the global population will be affected by myopia, with approximately 10% classified as high myopes. High myopia is characterized by axial elongation of the eye and is associated with an elevated risk of severe ocular complications, including early-onset cataracts, glaucoma, retinal detachment, choroidal neovascularization, myopic macular degeneration, and macular hemorrhage. Given its increasing prevalence and potential for vision-threatening outcomes, myopia constitutes a substantial public health issue, contributing to considerable healthcare and socioeconomic burdens. Therefore, the development of safe and effective interventions to mitigate the progression of myopia is of critical importance.

03

Conditions studied

  • Myopia Progression

Browse trials for

04

Who can participate

Ages eligible
5 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female children between 5 to 10 years of age.
  2. Children with refractive error of spherical equivalent -1.00 D up to -6.00 D in each eye.
  3. Children with active myopia progression of at least spherical equivalent -0.50 D within the last 12 months.
  4. Children with astigmatism of less than -1.50 D
  5. Children having distance vision correctable to logMAR 0.2 or better in both eyes.
  6. A difference between non-cycloplegic subjective spherical refraction and cycloplegic subjective spherical refraction of not greater than -1.00 D.
  7. Children with normal intraocular pressure of not greater than 21 mmHg in either eye.
  8. Children with normal ocular health other than myopia.
  9. Children must be in good general health with no history of cardiac or respiratory diseases as per investigator's discretion and does not affect the study treatment or subsequent follow-ups.
  10. No asthma-requiring medications in the past one year.
  11. No known allergy to atropine, cyclopentolate, proparacaine and benzalkonium chloride.
  12. Willing and able to comply with scheduled visits and other study procedures.
  13. Written from parent and assent from child has been obtained.

Exclusion criteria

Exclusion Criteria:

  1. History of or allergy to study drug and/or any of the study medication ingredients.
  2. Children with prior and/or concomitant use of other myopia control drugs, contact lens or spectacles (except normal spectacles including tinted/anti-glare glasses) etc.
  3. Children with congenital myopia.
  4. Children using Ortho K and Myopia Lens.
  5. Children with ocular or systemic diseases which may affect vision or refractive error.
  6. Children with any ocular condition wherein topical atropine is .
  7. Children with defective binocular function or stereopsis.
  8. Children with amblyopia (lazy eyes) or manifest strabismus including intermittent tropia.
  9. Previous or current use of atropine or pirenzepine.
  10. Children with any other conditions precluding adherence to the protocol including unwillingness to refrain from the use of other myopia control drug, contact lens or spectacles (except normal) spectacles including tinted/anti-glare glasses) etc. for the duration of the study.
  11. Children with any other condition which may put the subject to risk during study or affect study results based on investigator's judgement.
  12. Children participated in any clinical study within 30 days prior to randomization.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Active comparator
    Atropine Sulphate 0.025% w/v Eye Drops

    Participants will be instructed to administer one drop of Atropine Sulphate 0.025% w/v Eye Drops into each eye once daily at bedtime for a duration of 24 months.

    Drug: Low dose atropine sulfate eye drops

  • Placebo comparator
    Placebo

    Participants will be instructed to administer one drop of Placebo Eye Drops into each eye once daily at bedtime for a duration of 12 months and Atropine Sulphate 0.025% w/v Eye Drops from 13-24 months onwards.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. To demonstrate the superiority of eye drop formulation (Atropine Sulphate 0.025% w/v Eye Drops) against placebo determined by Spherical equivalent

    Spherical equivalent refraction determined by cycloplegic autorefraction from baseline to 12 months at each visit.

    Time frame: 12 months

Secondary outcomes

  1. To demonstrate continued efficacy of eye drop formulation (Atropine Sulphate 0.025% w/v Eye Drops) of 24 months with the comparison of 12 months by spherical equivalent

    Determination of rate of progression in year 2 vs year 1 via Spherical equivalent refraction as determined by cycloplegic autorefraction of 24 months with the comparison of 12 months.

    Time frame: 24 months

  2. To demonstrate the superiority of eye drop formulation (Atropine Sulpahte 0.025% w/v Eye Drops) against placebo by axial length

    Axial length as determined by non-contact partial coherence interferometry from baseline to 12 months at each visit.

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Jan 9, 2026
StartActual
Sep 17, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2029
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07329777
Lead sponsor
IDB VisionCare SDN BHD
Collaborators
Singapore National Eye Centre
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Sep 17, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2029 (estimated)
Last update
Jan 9, 2026

Study contacts

Nor Syakirah Zainal
Contact
atommy@idbvisioncare.com
+60143213786

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion